ALK/PI3K/AKT-IN-1

ALK/PI3K/AKT-IN-1 (Compound 45) inhibits the proliferation of cancer cell A549, H1975 and PC9 with an IC50 of 0.44, 0.83 and 1.51 μM. ALK/PI3K/AKT-IN-1 increases the expression of p21 and p27, inhibits the activity of CDK2 and p-Rb, arrests the cell cycle at G1 phase. ALK/PI3K/AKT-IN-1 inhibits the ALK/PI3K/AKT signaling pathway, promotes the depolarization of mitochondrial membrane potential, and inducing apoptosis in A549 cell. ALK/PI3K/AKT-IN-1 inhibits the formation and growth of A549 cell spheroids[1].

Product Specifications

CAS Number

[3050831-84-7]

UNSPSC

12352005

Target

Akt; Anaplastic lymphoma kinase (ALK) ; Apoptosis; CDK; Mitochondrial Metabolism; PI3K

Related Pathways

Apoptosis; Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; PI3K/Akt/mTOR; Protein Tyrosine Kinase/RTK

Field of Research

Cancer

Smiles

O=C(NC1=NC2=CC(C3=CC4=C(N=CN(CCC)C4=O)C=C3)=CC=C2S1)NC5=CC=C(F)C=C5

Molecular Formula

C25H20FN5O2S

Molecular Weight

473.52

References & Citations

[1]Linghu A, et al., Synthesis and Antitumor Activity of 6- (2-Aminobenzo[d]thiazol-5-yl) quinazolin-4 (3H) -one Derivatives. ACS Omega. 2025 Feb 10;10 (6) :5686-5698.